A Versatile Discovery Platform

Sonnet BioTherapeutics is leveraging its proprietary platform to develop a pipeline of single- and bi-functional therapies capable of stimulating and/or blocking immune-modulating targets.

Sonnet Concept

Our technology leverages a scaffold based on our proprietary albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets.

Following administration, the albumin-binding fragment attaches to naturally occurring albumin in the bloodstream and accumulates in inflamed tissue, including tumors.

By attaching a cytokine molecule to our albumin-binding fragment, we enable the cytokine to persist in the bloodstream and accumulate in the tumor micro-environment, affording it a greater chance to generate an anti-cancer immune response.

Platform Characteristics

  • Single domain antibody fragment platform (ScFv and VhH).
  • Enhanced pharmacokinetics and targeting of the tumor environment via albumin delivery.
  • Validated targets initially focused on rH-cytokines.
  • Dual targeting feasible – combination immune oncology therapeutics engineered into a single product.
  • Able to activate and sustain an immune response that selectively targets tumors.
  • Modular scaffold that can be customized to yield a broad array of multi-targeted therapeutics.